SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
Report on Form 6-K dated November 30, 2007
(Commission File No. 1-15024)
Novartis AG
(Name of Registrant)
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F: x Form 40-F: o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes: o No: x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes: o No: x
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes: o No: x
|
|
|
Novartis International AG |
|
|
|
|
|
- Investor Relations Release - |
||
Novartis completes its fifth share repurchase program
Basel, November 30, 2007 — Novartis has completed its fifth share repurchase program initiated on July 24, 2007, and during which 63,173,000 Novartis shares were purchased for a total of CHF 4 billion. The average purchase price per share was CHF 63.32.
Novartis intends to propose to shareholders at the next General Meeting in February 2008 to cancel all shares repurchased in the fifth program as well as the remaining 22,175,000 shares from the fourth program. The fourth share repurchase program was completed in July 2007. As a result, it is intended to cancel a total of 85,348,000 shares, which corresponds to 3.13% of the registered Novartis share capital.
# # #
Novartis Media Relations
John Gilardi
Novartis Global Media Relations
+41 61 324 3018 (direct)
+41 79 596 1408 (mobile)
john.gilardi@novartis.com
e-mail: media.relations@novartis.com
Novartis Investor Relations
|
International |
|
North America |
|
|
|
Ruth Metzler-Arnold |
|
Jill Pozarek |
|
+1 212 830 2445 |
|
Katharina Ambuehl |
|
Edwin Valeriano |
|
+1 212 830 2456 |
|
Pierre-Michel Bringer |
|
|
|
|
|
Jason Hannon |
|
|
|
|
|
Thomas Hungerbuehler |
|
|
|
|
|
Richard Jarvis |
|
|
|
|
|
Isabella Zinck |
|
|
|
|
|
|
|
|
|
|
|
Central phone no: +41 61 324 7944 |
|
|
|
|
|
e-mail: investor.relations@novartis.com |
|
e-mail: investor.relations@novartis.com |
||
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Novartis AG |
|||
|
|
|
|||
|
|
|
|||
|
Date: November 30, 2007 |
By: |
/s/ MALCOLM B. CHEETHAM |
|
|
|
|
|
|
||
|
|
Name: |
Malcolm B. Cheetham |
||
|
|
Title: |
Head Group Financial |
||
|
|
|
Reporting and Accounting |
||
3